Beste Therapeuten in Türkei - TOP -107 Ärzte

• Experte für Physiotherapie bei muskuloskelettalen und neurologischen Erkrankungen.
• Gründung von Fizyomer Terapia, einem renommierten Rehabilitationszentrum.
• Beherrscht Methoden wie manuelle Therapie, Bewegung und Elektrotherapie.
• International tätig, insbesondere in Europa und im Nahen Osten.
• Besitzt Zertifizierungen in Physiotherapie und Rehabilitation.
• Mitglied globaler Physiotherapie- und Rehabilitationsorganisationen.
• Bietet Online-Konsultationen für die Fernversorgung von Patienten an.

Ich bin seit 1993 als Zahnarzt tätig, 1 Jahr in Ankara, 5 Jahre in Kayseri und die restlichen 24 Jahre in Istanbul.

Obwohl ich die letzten 6 Jahre hauptsächlich mit Managementprozessen verbracht habe, macht es mir besonders viel Freude, mit unseren ängstlichen Patienten zu arbeiten und sie an zahnärztliche Behandlungen zu gewöhnen. Aufgrund dieser Fähigkeit habe ich mich vor einigen Jahren der Hypnotherapie zugewandt. Ich setze meinen Weg fort, indem ich mich in Managementprozessen der Ambulanz und Hypnotherapie verbessere.

Berufserfahrung

1993-1999 Zahnärztliche Poliklinik

1999-2005 Şifa Medical Center

2005-2009 Zahnärztliche Poliklinik

2009-2016 Tuzla Medical Center

2016 Ulusoydent Poliklinik für Mund- und Zahngesundheit

Ausbildung und Qualifikationen

Fakultät für Zahnmedizin der Hacettepe-Universität

Management von Gesundheitseinrichtungen der Universität Istanbul.

Master-Abschluss

19. Mai Universitäres Gesundheitsmanagement,

Gesundheitsministerium Getat Trainings Hypnotherapie.

Zertifikate

Gesundheitsministerium Getat Trainings Hypnotherapie

Therapie zur Raucherentwöhnung

Regressionshypnose

HYT

Ericsonsche Hypnotherapie

Hypnoanästhesie

Selbsthypnose

Sprachen

Englisch

Türkisch

Interessen

Malerei

Musik hören

Reisen

Dr. Özgür Ağlamış ist eine staatlich geprüfte kosmetische Gynäkologin, die sich auf vaginale Verjüngung und Vaginismus-Behandlungen spezialisiert hat. Sie hat ihren Abschluss an der Gazi-Universität in Ankara gemacht und eine Spezialisierung am Zekai Tahir Burak Women's Health Training & Research Hospital absolviert. Dr. Ağlamış ist sowohl in chirurgischen als auch in nicht-chirurgischen Protokollen erfahren und spricht fließend Englisch.

Erfahrung

2019 - 2022

Universität für Gesundheitswissenschaften, Medizinische Fakultät, Stadtkrankenhaus Ankara, Kardiologische Klinik, Ankara

2017 - 2019

Universität für Gesundheitswissenschaften, Medizinische Fakultät, Türkei, Höheres Spezialisierungs- und Forschungskrankenhaus, Kardiologische Klinik, Ankara,

2012 - 2017

Türkiye Höheres Spezialisierungs- und Forschungskrankenhaus, Kardiologische Klinik, Ankara,

2012 - 2017

TR Karabük Universität, Medizinische Fakultät, Abteilung für Kardiologie

2006 - 2006

Türkiye Höheres Spezialisierungs- und Forschungskrankenhaus, Kardiologische Klinik, Ankara,

2001 - 2006

Türkiye Höheres Spezialisierungs- und Forschungskrankenhaus, Kardiologische Klinik, Ankara,

1996 - 2001

Türkiye Höheres Spezialisierungs- und Forschungskrankenhaus, Kardiologische Klinik, Ankara,

Ausbildung

2017 Karabük Universität, Medizinische Fakultät, Abteilung für Kardiologie

2006 Türkiye Höheres Spezialisierungs- und Forschungskrankenhaus, Kardiologische Klinik

2001 Türkiye Höheres Spezialisierungs- und Forschungskrankenhaus, Ankara, Kardiologie

1996 Universität Ankara, Medizinische Fakultät

Erfahrung

2021 - 2022

Klinischer Manager für Strahlenonkologie, Medicana International Istanbul Hospital

2021 - 2022

Abteilung für Strahlenonkologie, Medizinische Fakultät der Biruni-Universität

2020 - 2021

Klinischer Manager für Strahlenonkologie, Medicana International Istanbul Hospital

2017 - 2020

Klinischer Manager für Strahlenonkologie, Neolife Medical Center

2016 - 2017

Abteilung für Strahlenonkologie, Medizinische Fakultät der Eskişehir Osmangazi-Universität

2011 - 2016

Abteilung für Strahlenonkologie, Medizinische Fakultät der Eskişehir Osmangazi-Universität

2010 - 2011

Abteilung für Strahlenonkologie, Medizinische Fakultät der Eskişehir Osmangazi-Universität

2008 - 2010

Klinik für Strahlenonkologie, Samsun Ausbildungs- und Forschungskrankenhaus (Bildungskoordinator)

2006

Medizinische Fakultät, Dokuz-Eylül-Universität

2006 - 2008

Klinik für Radioonkologie, Staatliches Krankenhaus Samsun Mehmet Aydın (Pflichtdienst)

2000 - 2006

Medizinische Fakultät, Dokuz-Eylül-Universität

Ausbildung

2022

Medizinische Fakultät der Biruni-Universität, Abteilung für Strahlenonkologie, Fakultätsmitglied, Professor Doktor

2022

Bachelor-Programm der Fakultät für offene Bildung der Anadolu-Universität, Kulturerbe und Tourismus

2021

Feyziye Schools Foundation Işık University Health Services Berufsschule, Fakultätsmitglied, Außerordentlicher Professor Doktor

2017

Medizinische Fakultät der Universität Eskişehir Osmangazi, Abteilung für Strahlenonkologie, Fakultätsmitglied

2017

Medizinische Fakultät der Universität Eskişehir Osmangazi, Abteilung für Strahlenonkologie, außerordentlicher Professor

2006

Samsun Ausbildungs- und Forschungskrankenhaus, Facharzt, Pflichtdienst

2006

Medizinische Fakultät der Dokuz Eylül-Universität, Abteilung für Strahlenonkologie, Medizinische Spezialisierung

1998

Ege Universität, Medizinische Fakultät

PROFESSIONAL EXPERIENCE

2011-2012
Erzurum Koprukoyu State Hospital
Department: General Medicine

2012-2017
Istanbul University Cerrahpaşa Medical Faculty
Department: Internal Medicine

06/2017-10/2017
Istanbul Gaziosmanpasa Taksim Training and Research Hospital
Department: Internal Medicine

10/2017-11/2018
Istanbul University Istanbul Medical Faculty
Department: Allergy and Immunology Fellowship

2018/2022
Istanbul University Oncology Institute
Department: Medical Oncology Fellowship

2022-2023
Tekirdag City Hospital
Department: Medical Oncology Specialist

2023-present
Istanbul Medipol University Medipol Bahcelievler Private Hospital
Department: Medical Oncology Assoc. Prof.

EDUCATION

2005-2011
Medical Education
Sivas Cumhuriyet University Medical Faculty, Sivas, Turkey

2012-2017
Internal Medicine
Istanbul University Cerrahpaşa Medical Faculty, Department of Internal Medicine, Istanbul, Turkey

2017-2018
Allergy-Immunology Fellowship
Istanbul University Istanbul Medical Faculty
Department of Internal Medicine, Division of Allergy and Immunology, Istanbul, Turkey

2018-2022
Medical Oncology Fellowship
Istanbul University Oncology Institute, Department of Medical Oncology, Istanbul, Turkey

2022
ESMO Board Certification in Medical Oncology
10th September 2022 in Paris, France.

2023
Medical Oncology Assoc. Prof.
Istanbul Medipol University Department of Medical Oncology, Istanbul, Turkey

INTERNATIONAL CLINICAL TRIALS:

1. Astefania - ROCHE

• Title: A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
• Role: Subinvestigator

2. PFİZER

• Title: A Study Of Lorlatinib Versus Crizotinib In First-Line Treatment Of Patients With ALK-Positive NSCLC
• Role: Subinvestigator

3. RECITE - AMGEN

• Title: Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer
• Role: Subinvestigator

4. NAVIGATE - BAYER

• Title: A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors
• Role: Subinvestigator

5. RUBY - Tesaro (PRA)

• Title: A Phase 3, Randomized, Double-blind, Multicenter Study of Dostarlimab (TSR-042) Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Patients With Recurrent or Primary Advanced Endometrial Cancer
• Role: Subinvestigator

6. ENGOT-ov43/GOG-3036 - MSD

• Title: Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK001/ENGOT-ov43/GOG-3036)
• Role: Subinvestigator

7. ASTRA ZENECA

• Title: To Study Clinical Effectiveness and Safety of Olaparib Monotherapy in Metastatic Breast Cancer Patients.
• Role: Subinvestigator

8. ROSY-O - ASTRA ZENECA

• Title: Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib
• Role: Subinvestigator
•  

INTERNATIONAL PUBLICATIONS

I. Published journal articles indexed by SCI, SSCI, and AHCI

Weekly Paclitaxel in Classic Kaposi Sarcoma

• Authors: Paksoy, N., Khanmammadov, N., Doğan, İ., Ferhatoğlu, F., Ahmed, M. A., Karaman, S., & Aydiner, A.
• Journal: Medicine, 102(5)

Carboplatin Desensitization in Ovarian Carcinoma

• Authors: Paksoy, N., Khanmammadov, N., Doğan, İ., Ferhatoğlu, F., Yildiz, A., Ak, N., & Aydiner, A.
• Journal: Medicine, 101(45), e31726

High-Dose Chemotherapy for Ewing’s Sarcoma

• Authors: Paksoy, N., Ferhatoglu, F., Dogan, İ., Khanmammadov, N., Celik, A. I., Gulbas, Z., & Başaran, M.
• Journal: Medicine, 101(49), e32213

Multidrug Refractory TFE3(+) Renal Cell Carcinoma

• Authors: Paksoy, Nail, et al.
• Journal: Journal of Oncology Pharmacy Practice, 2022, 28.1: 215-221

Crizotinib Efficacy in NSCLC with MET Alterations

• Authors: Gürbüz, M., Kiliçkap, S., Bilici, A., Karadurmuş, N., Sezer, A., Şendur, M. A. N., ... & Demirkazik, A.
• Journal: Medicine, 101(50), e32368

Clinicopathological Features in ALK Mutant NSCLC

• Authors: Dogan, I., Gurbuz, M., Paksoy, N., Ferhatoglu, F., Vatansever, S., Saip, P., ... & Aydiner, A.
• Journal: Medicine, 101(34)

PSMA-Based Tumor Burden in Prostate Cancer

• Authors: HAS SIMSEK, Duygu, et al.
• Journal: Annals of Nuclear Medicine, 2021, 35.6: 680-690

Atezolizumab in Metastatic Urothelial Carcinoma

• Authors: TURAL, Deniz, et al.
• Journal: European Urology Focus, 2021, 7.5: 1061-1066

Pulmonary Sarcomatoid Carcinoma

• Authors: FERHATOGLU, Ferhat, et al.
• Journal: Oncology Research and Treatment, 2021, 44.11: 590-601

Prognostic Factors in Atezolizumab-Treated Urothelial Carcinoma

• Authors: TURAL, Deniz, et al.
• Journal: International Journal of Clinical Oncology, 2021, 26.8: 1506-1513

Atezolizumab with Chemotherapy in Small Cell Lung Cancer

• Authors: GÜRBÜZ, Mustafa, et al.
• Journal: Journal of Cancer Research and Clinical Oncology, 2022, 1-9

FOLFIRINOX vs. Gemcitabine + Nab-Paclitaxel in Pancreatic Cancer

• Authors: AY, Seval, et al.
• Journal: Journal of Chemotherapy, 2022, 1-7

Trastuzumab Emtansine in Older HER2-Positive Breast Cancer Patients

• Authors: CIL, Ibrahim, et al.
• Journal: Tumori Journal, 2022, 108.1: 19-25

Real-Life Efficacy of Osimertinib in Advanced NSCLC

• Authors: HIZAL, Mutlu, et al.
• Journal: Journal of Cancer Research and Clinical Oncology, 2022, 148.6: 1501-1508

ALK-Positive Cells Percentage and Alectinib Efficacy

• Authors: Hizal, M., Bilgin, B., Paksoy, N., Atcı, M. M., Kahraman, S., Kılıçkap, S., ... & Şendur, M. A. N.
• Journal: Journal of Cancer Research and Clinical Oncology, 149(8), 4141-4148

Real-World Data on Alectinib in ALK-Positive NSCLC

• Authors: Hizal, M., Bilgin, B., Paksoy, N., Kılıçkap, S., Atcı, M. M., Kahraman, S., ... & Şendur, M. A. N.
• Journal: Future Oncology, 18(23), 2573-2582

Prognostic Factors in Metastatic RCC with T790M Mutation

• Authors: Dogan, I., Iribas, A., Paksoy, N., Vatansever, S., & Basaran, M.
• Journal: Journal of Cancer Research and Therapeutics

FLOT Regimen in Metastatic Gastric Cancer

• Authors: Tastekin, D., Paksoy, N., Dogan, I., Ferhatoglu, F., Khanmammadov, N., Bozbey, H. U., & Karabulut, S.
• Journal: Journal of Cancer Research and Therapeutics

Desensitization Protocol in Lenalidomide Hypersensitivity Reactions

• Authors: DEMIR, Semra, et al.
• Journal: Annals of Allergy, Asthma & Immunology, 2019, 123.4: 394-397

Factors Associated with Diagnostic Skin Test Positivity in PPI Hypersensitivity

• Authors: ÖZDEMIR, Seçil Kepil, et al.
• Journal: Allergy, 2019, 74.6: 1187-1190

Efficacy of Capecitabine and Temozolomide in Neuroendocrine Tumors

• Authors: Ünal, Ç., Azizy, A., Karabulut, S., Taştekin, D., Akyıldız, A., Yaşar, S., ... & Sağlam, S.
• Journal: The Oncologist, oyad257

Subsequent Treatments in Hormone-Positive Breast Cancer Progression

• Authors: Karacin, C., Oksuzoglu, B., Demirci, A., Keskinkılıç, M., Baytemür, N. K., Yılmaz, F., ... & Hacıbekiroğlu, İ.
• Journal: BMC cancer, 23(1), 192

Termination of Trastuzumab in HER2-Positive Metastatic Breast Cancer

• Authors: Dogan, I., Aydin, E., Khanmammadov, N., Paksoy, N., Saip, P., & Aydiner, A.
• Journal: Scientific Reports, 13(1), 8779

Long-term Outcomes and Predictors of Recurrence in Node-Negative Early Stage Breast Cancer

• Authors: Dogan, I., Aydin, E., Khanmammadov, N., Paksoy, N., Ferhatoğlu, F., Ak, N., ... & Aydiner, A.
• Journal: Journal of Cancer Research and Clinical Oncology, 1-9

Prognostic Factors Influencing PFS in HER2-Positive Metastatic Breast Cancer

• Authors: Doğan, İ., Paksoy, N., Ak, N., Vatansever, S., Saip, P., & Aydıner, A.
• Journal: European Journal of Breast Health, 19(2), 128

Treatment Efficacy of Ribociclib or Palbociclib plus Letrozole in Metastatic Breast Cancer

• Authors: Kahraman, S., Erul, E., Seyyar, M., Gumusay, O., Bayram, E., Demirel, B. C., ... & Nahit Sendur, M. A.
• Journal: Future Oncology, 19(10), 727-736

Efficacy and Safety of Sorafenib in Adult Metastatic Osteosarcoma Patients

• Authors: Dogan, I., Paksoy, N., & Basaran, M.
• Journal: Journal of Cancer Research and Therapeutics

Single-Agent Temozolomide as Salvage Therapy in Heavily Pretreated Metastatic Sarcoma Patients

• Authors: Dogan, I., Paksoy, N., & Basaran, M.
• Journal: Journal of Cancer Research and Therapeutics

Outcomes and Prognostic Factors in Metastatic Renal Cell Carcinoma with Brain Metastases

• Authors: Dogan, I., Iribas, A., Paksoy, N., Vatansever, S., & Basaran, M.
• Journal: Journal of Cancer Research and Therapeutics

FLOT Regimen in First-Line Treatment of Metastatic Gastric Cancer

• Authors: Tastekin, D., Paksoy, N., Dogan, I., Ferhatoglu, F., Khanmammadov, N., Bozbey, H. U., & Karabulut, S.
• Journal: Journal of Cancer Research and Therapeutics

Prognostic Factors of Perioperative FLOT Regimen in Operable Gastric Cancer

• Authors: Erol, C., Sakin, A., Basoglu, T., Ozden, E., Cabuk, D., Dogan, M., ... & Sendur, M. A. N.
• Journal: [Not specified]

Efficacy and Outcomes of Systemic Chemotherapy in Posttransplant Kaposi Sarcoma

• Authors: Khanmammadov, N., Paksoy, N., Doğan, I., Ferhatoğlu, F., Saip, P., & Aydiner, A.
• Journal: Medicine, 102(39), e35383

Comparison of Second-Line Treatments in Metastatic Renal Cell Carcinoma

• Authors: Pehlivan, M., Paksoy, N., Aydin, E., Basaran, M., & Ekenel, M.
• Journal: Medicine, 102(41), e35245

Toxicity Management and Effectiveness of Regorafenib in Advance GIST Patients: A Real-world Study - Authors: Paksoy, N., Ferhatoğlu, F., Doğan, İ., Khanmammadov, N., Bozbey, H. U., Karabulut, S., & Taştekin, D. - Journal: TURKISH JOURNAL OF ONCOLOGY, 1(1)

Demographic and Clinical Features and Factors Associated with Survival in Patients with Primary Glomerulonephritis: Single Tertiary Center Experience - Authors: Paksoy, N., Trabulus, S., Seyahi, N., & Altiparmak, M. R. - Journal: Namik Kemal Tip Dergisi, 11(1)

Efficacy of Sorafenib in Symptomatic Patients with Pretreated Progressive Desmoid Tumors - Authors: Paksoy, N., Ferhatoglu, F., Dogan, I., Ak, N., Pehlivan, M., Ekenel, M., & Basaran, M.

Nodal Response to Neoadjuvant Chemotherapy is a Better Predictive Factor of Survival Than Miller-Payne Scoring in Breast Cancer - Authors: Ak, Naziye, et al. - Journal: Journal of Oncological Sciences, 7.2: 42-49

Evaluation of Prognostic and Predictive Values of Hemogram Parameters in Patients with Advanced Stage Ovarian Carcinoma - Authors: Ak, Naziye, et al. - Journal: Turkish Journal of Oncology/Türk Onkoloji Dergisi, 2021, 36.4

Identifying Risk Factors Associated with Survival and Drug-Related Toxicities in Imatinib-Resistant Gastrointestinal Stromal Tumor (GIST) Patients Treated with Sunitinib - Authors: Ferhatoglu, F., Karabulut, S., Paksoy, N., & Tastekin, D.

Real-life Outcomes of ROS1 Fusion-positive Metastatic Lung Cancer Patients who were Treated with Crizotinib - Authors: Dogan, İ., Khanmammadov, N., Paksoy, N., Ferhatoglu, F., Aydın, E., Vatansever, S., & Aydine, A. - Journal: TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY

Predictors of the acquisition of T790M mutation in EGFR-mutant metastatic lung cancer patients who were treated with EGFR inhibitors - Authors: Dogan, I., Khanmammadov, N., Paksoy, N., Vatansever, S., Saip, P., & Aydıner, A. - Journal: Eurasian Journal of Pulmonology

Laterality of Adrenal Gland Metastasis in Lung Cancer: Results of a Comparative Study - Authors: Ferhatoglu, F., Gagatay, T., Okumus, G., Aydiner, A., Paksoy, N., Ak, N., ... & Saip, P. - Journal: Eurasian Journal of Medical Investigation, 7(2)

Poor Risk Factors Affecting Cancer Patients Infected with Covid-19: A Retrospective Comparative Study from a Pandemic Hospital - Authors: Ferhatoglu, F., Kapağan, T., Paksoy, N., Ak, N., Medetalibeyoğlu, A., Şenkal, N., ... & Vatansever, S. - Journal: Turk Onkoloji Dergisi, 38(1)

Systemic Treatment Outcomes of Progressive Medullary Thyroid Carcinoma from the Registries of a Tertiary Cancer Center - Authors: Ferhatoglu, F., Paksoy, N., & Başaran, M. - Journal: Namik Kemal Tip Dergisi, 10(4)

Evaluation of clinical features and risk factors related to late recurrence (> 5 years) in patients with breast cancer - Authors: Ferhatoglu, F., Aydiner, A., & Paksoy, N. - Journal: Journal of Surgery & Medicine (JOSAM), 6(12)

Assessing the Clinical Impact of Lutetium-177 DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) on Metastatic Neuroendocrine Tumors: A Multicenter Real-World Data from Türkiye

Thesis:

Istanbul University Cerrahpaşa Medical Faculty, Internal Medicine Department PAKSOY, Nail. Demographical, clinical characteristics and survival factors in patients withprimary glomerulonephritis: Cerrahpasa Medical Faculty Experience. (2016)

International Refereed Congress / Symposium Publications in Proceedings (ASCO/ESMO Abstracts)

Prognostic factors influencing progression-free survival in HER2 positive metastatic breast cancer patients who treated with lapatinib and capecitabine combination

• Authors: Dogan, I., Paksoy, N., Ak, N., Vatansever, S., Saip, P., & Aydiner, A. (2022)

Efficacy of regorafenib and 5-fluorouracil-based rechallenge treatment in the third-line treatment of metastatic colorectal cancer: A Turkish oncology group study

• Authors: Şenocak Taşçi, E., Oyan, B., Sonmez, O., Mutlu, A. U., Atcı, M. M., Oner, I., ... & Gulmez, A. (2022)

Long-term outcomes and predictors of recurrence in patients with early-stage node-negative breast cancer

• Authors: Dogan, I., Aydin, E., Paksoy, N., Ferhatoglu, F., Ak, N., Ibis, K., ... & Aydiner, A. (2021)

Efficacy of temozolomide in pretreated patients with metastatic sarcoma

• Authors: Paksoy, N., Dogan, I., Ekenel, M., & Basaran, M. (2021)

Efficacy of sorafenib in symptomatic patients with pretreated progressive desmoid tumors

• Authors: Ferhatoglu, F., Paksoy, N., Dogan, I., Ak, N., Pehlivan, M., Ekenel, M., & Basaran, M. (2021)

Efficacy of sorafenib in heavily pretreated adult patients with metastatic osteosarcoma

• Authors: Paksoy, N., Dogan, I., Ekenel, M., & Basaran, M. (2021)

Outcomes and prognostic factors in metastatic renal cell carcinoma patients with brain metastases

• Authors: Dogan, İ., Iribas, A., Paksoy, N., Ekenel, M., Vatansever, S., & Basaran, M. (2021)

Association of response to first-line chemotherapy with the efficacy of atezolizumab in patients with metastatic urothelial carcinoma

• Authors: Tural, D., Olmez, O. F., Sümbül, A. T., Artac, M., Ozhan, N., Akar, E., ... & Erman, M. (2021)

Safety and survival in adult women with platinum-sensitive relapsed BRCA mutant ovarian cancer: A study of patients in Olaparib Turkey Early Access Program—LynTurk study

• Authors: Esin, E., Ahmed, M. A., Yıldırım, H. Ç., Mandel, N. M., Erdemoglu, E., Sari, M., ... & Paydas, S. (2023)

Atezolizumab in patients with metastatic urothelial carcinoma who have progressed after first-line chemotherapy: Results of real-life experiences

• Authors: Tural, D., Ölmez, Ö. F., Sümbül, A. T., Artaç, M., Özhan, N., Akar, E., ... & Kılıçkap, S. (2021)

Experience

2016 - 2022

ISTANBUL MEDIPOL UNIVERSITY

2010 - 2016

BEZM-I ÂLEM FOUNDATION UNIVERSITY

2010 - 2015

Bezmialem Vakif University Faculty of Medicine

2009 - 2010

Bagcilar Training and Research Hospital

2009 - 2010

ISTANBUL BAGCILAR TRAINING AND RESEARCH HOSPITAL

1997 - 2009

ISTANBUL HASEKI TRAINING AND RESEARCH HOSPITAL

1997 - 2009

Haseki Training and Research Hospital

Education

2016

BEZM-I ÂLEM FOUNDATION UNIVERSITY, DEPARTMENT OF ANESTHESIOLOGY AND REANIMATION

1997

Istanbul Haseki Training and Research Hospital, Anesthesiology and Reanimation

1993

ISTANBUL HASEKI TRAINING AND RESEARCH HOSPITAL, Medical Specialization

1989

Istanbul University, Faculty of Medicine

1983

ISTANBUL UNIVERSITY, CERRAHPAŞA FACULTY OF MEDICINE, FACULTY OF MEDICINE

Experience

2018 - 2022

Health Sciences University – Şişli Hamidiye Etfal Training and Research Hospital

2016 - 2018

Diyarbakır Memorial Dicle Hospital Cardiology Clinic

2010 - 2010

Dicle University Faculty of Medicine, Department of Cardiology

2010 - 2016

Private Veni Vidi Hospital, Cardiology Clinic Supervisor

2006 - 2010

Dicle University Faculty of Medicine, Department of Cardiology

2005 - 2006

Urfa State Hospital

1999 - 2005

Turkey High Specialization Training and Research Hospital

1998 - 1999

Duruca Health Center

Education

2018

Health Sciences University, Cardiology

2010

Dicle University, Department of Cardiology

2005

Cardiology Turkey High Specialization Training and Research Hospital, Medical Specialization

1998

Ege University, Faculty of Medicine

Experience

2016 - 2019 Özel Gebze Konak Hastanesi

2014 - 2015 Özel Medicana Çamlıca Hastanesi

2013 - 2014 Özel Batman Hastanesi

2011 - 2013 Batman Bölge Devlet Hastanesi

Üsküdar Üniversitesi

Gazi Üniversitesi Tıp Fakültesi

Education

2011 Bezmialem Vakıf Üniversitesi Tıp Fakültesi, Fiziksel Tıp ve Rehabilitasyon

2005 Marmara Üniversitesi, İngilizce Tıp Fakültesi

Education: 

İstanbul Pertevniyal Anatolian High School 

Trakya University Faculty of Medicine 

İstanbul Okmeydanı Training And Research Hospital Family Practice 

Experience: 

Liv Hospital Ulus 2021-  

Acıbadem Fulya Hospital 

Adıyaman Sincik District State Hospital 

Okmeydanı Training and Research Hospital 

İstanbul Gaziosmanpaşa Karlıtepe A.H.D, Bağlarbaşı A.H.D. and Pazariçi A.H.D

Memberships: 

Turkish Medical Association (Istanbul Chamber of Doctors) 

TAHUD (Turkish Family Physicians Specialty Association)

• Experte für plastisch-chirurgische Therapie bei Verbrennungen, Wunden und Narbenrevisionen.
• Bietet persönliche Beratungen im Apex Medical Center und in der PARLA CLINIC.

• Experte für therapeutische Behandlungen, der eine patientenorientierte Betreuung gewährleistet.

Dr. Nazli KORKMAZ, a renowned expert in the field of genital aesthetic surgery. The clinic, located in Istanbul, Turkey, is recognized for its exceptional medical standards and commitment to patient well-being. Dr. Nazli Korkmaz, who bases her treatments on the principle of "catering to all aspects of women's health," takes a comprehensive approach to women's well-being, sexuality, and aesthetics, addressing the unique needs of women throughout their lives. With a dedicated team, Surgeon Dr. Nazli KORKMAZ ensures a comfortable and professional experience, delivering optimal results when the patient enters her clinic. The clinic's medical team recognizes that each patient has individual requirements and expectations. Therefore, they customize every visit to meet patients' needs, providing personalized care at every step.